<?xml version="1.0" encoding="UTF-8"?>
<ref id="b21-1040797">
 <label>21.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>O’Brien</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Jones</surname>
    <given-names>JA</given-names>
   </name>
   <name>
    <surname>Coutre</surname>
    <given-names>SE</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study</article-title>. 
  <source>Lancet Oncol</source>. 
  <year>2016</year>;
  <volume>17</volume>(
  <issue>10</issue>):
  <fpage>1409</fpage>–
  <lpage>1418</lpage>.
  <pub-id pub-id-type="pmid">27637985</pub-id>
 </mixed-citation>
</ref>
